慢性丙型肝炎患者中TT病毒对干扰素联合利巴韦林治疗的反应。

Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C.

作者信息

Moreno Javier, Moraleda Gloria, Barcena Rafael, Mateos Mluisa, del Campo Santos

机构信息

Department of Gastroenterology, Hospital Ramony Cajal, Ctra. Colmenar, Km 9.1, 28034 Madrid, Spain.

出版信息

World J Gastroenterol. 2004 Jan;10(1):143-6. doi: 10.3748/wjg.v10.i1.143.

DOI:10.3748/wjg.v10.i1.143

PMID:14695786

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4717067/

Abstract

AIM

TT virus (TTV) is a newly described DNA virus related to postransfusion hepatitis that produces persistent viremia in the absence of clinical manifestations. PEG-IFN plus ribavirin have been useful in the treatment of chronic hepatitis C infection. This study investigated the responses of TT virus (TTV) and hepatitis C virus (HCV) to PEG-IFN plus ribavirin therapy.

METHODS

Fifteen patients infected with HCV were treated with PEG-IFN(0.5 microg/body weight/week) and ribavirin (1 000 mg-1 200 mg/daily) for 48 weeks. Blood samples were drawn at the beginning and the end of the therapy. Serum TTV DNA and HCV RNA were quantified by real time PCR.

RESULTS

At the beginning of treatment, TTV infection was detected in 10/15 (66.6%) of HCV-infected patients. Loss of serum TTV DNA at the end of therapy occurred in 6/10 (60%) patients. Out of these 6 patients, 4 (67%) became positive for TTV DNA after 6 months of therapy. Regarding HCV viremia, 11/15 (73%) patients were negative for serum HCV RNA after 48 weeks of therapy, 7/11 (64%) of these cases also became negative for TTV DNA following the combined treatment. In the 3/4 (75%) patients who were positive for HCV RNA at the end of therapy, TTV DNA was detected as well. Sustained HCV response at 6 months after treatment was 53% (8/15).

CONCLUSION

No TTV sustained response can be achieved in any patient after PEG-IFN plus ribavirin administration.

摘要

目的

TT病毒（TTV）是一种新发现的与输血后肝炎相关的DNA病毒，在无临床表现的情况下可产生持续性病毒血症。聚乙二醇干扰素（PEG-IFN）联合利巴韦林已被用于治疗慢性丙型肝炎感染。本研究调查了TT病毒（TTV）和丙型肝炎病毒（HCV）对PEG-IFN联合利巴韦林治疗的反应。

方法

15例HCV感染患者接受PEG-IFN（0.5μg/体重/周）和利巴韦林（1000mg-1200mg/每日）治疗48周。在治疗开始和结束时采集血样。通过实时PCR定量血清TTV DNA和HCV RNA。

结果

治疗开始时，15例HCV感染患者中有10例（66.6%）检测到TTV感染。治疗结束时，10例患者中有6例（60%）血清TTV DNA转阴。在这6例患者中，4例（67%）在治疗6个月后TTV DNA再次转为阳性。关于HCV病毒血症，治疗48周后，15例患者中有11例（73%）血清HCV RNA转阴，其中7例（64%）在联合治疗后TTV DNA也转阴。治疗结束时HCV RNA仍为阳性的4例患者中有3例（75%）也检测到TTV DNA。治疗后6个月的持续HCV反应率为53%（8/15）。